The US Bankruptcy Court approved the second amended plan of liquidation and related disclosure statement of MabVax Therapeutics Holdings, Inc. on March 5, 2020. The debtor has filed its second amended plan in the Court on January 8, 2019. As per the amended plan, administrative expense claims of $0.33 million, statutory fees, post-confirmation fees and expenses and professional compensation claims will be paid in full in cash on the effective date. Secured claims will either be paid by collateral securing or cash or any other treatment. Priority tax claims and non-tax claims of $0.07 million will be paid in full in cash. 510(a), 510(b) and 510(c) subordinated Claims and inter-company claims will be deemed extinguished. General unsecured claims of $15.89 million will be paid 3%, i.e., $0.48 million, in the form of available cash, while all equity interests shall be cancelled. The plan will be funded through sale of assets of approximately $2.30 million and available cash in hand of $0.30 million.